OHSU

IRB #

IRB00009893

Title

S1203: A Randomized Phase III Study of Standard Cytarabine plus Daunorubicin (7+3) Therapy or Idarubicin with High Dose Cytarabine (IA) versus IA with Vorinostat (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML)

Principal Investigator

Rachel Cook

Study Purpose

Determine the difference in effects of standard daunorubicin plus Cytarabine (AraC) vs. standard idarubicin plus AraC vs. idarubicin plus AraC and vorinostat (study drug).

Medical Condition(s)

Acute Myeloid Leukemia (AML)

Eligibility Criteria

- Greater than 18 and less than 60 years of age.
- Have previously untreated Acute Myeloid Leukemia (AML).
- Must not be pregnant or nursing.

Age Range

18 - 60

Healthy Volunteers Needed

No

Duration of Participation

Up to 5 years after registration.

Minors Included

No

Contact

Nan Subbiah
503-494-4603
subbiahn@ohsu.edu

Knight Clinical Trials Office Information Line
503-494-1080
trials@ohsu.edu

Sponsor

Southwest Oncology Group (SWOG)

Recruitment End

Compensation Provided

No


Go Back